Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Metabolome Technologies Buyback Yield % Chart
TSE:6090 vs TMO, DHR, IDXX: Buyback Yield % Comparison
For the Diagnostics & Research subindustry, Human Metabolome Technologies's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Human Metabolome Technologies Buyback Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Human Metabolome Technologies's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Metabolome Technologies (TSE:6090) has a Buyback Yield % of 0.00 as of Jul. 21, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Human Metabolome Technologies and its competitors. According to the industry distribution chart, Human Metabolome Technologies ranks #999999 out of 90 companies in the Medical Diagnostics & Research industry.
Is Human Metabolome Technologies' Buyback Yield % too high?
Human Metabolome Technologies' current Buyback Yield % is 0.00. Based on the distribution chart, Human Metabolome Technologies ranks #999999 out of 90 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Human Metabolome Technologies has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' Buyback Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Human Metabolome Technologies ranks #999999 out of 90 companies for Buyback Yield %. This places Human Metabolome Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Diagnostics & Research company?
A good Buyback Yield % depends on the Medical Diagnostics & Research industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Human Metabolome Technologies and its competitors. Human Metabolome Technologies's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Fairly Valued. The stock's GF Value™ is 円530.33, compared to a current price of 円586.00 — trading 10.5% above its estimated fair value. The current Buyback Yield % is 0.00. Human Metabolome Technologies' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current Buyback Yield % is 0.00 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?
Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be overvalued.
The current stock price of 円586.00 is trading 10.5% above its estimated GF Value™ of 円530.33.
GuruFocus considers Human Metabolome Technologies to be Fairly Valued.
Key valuation signals for TSE:6090:
Buyback Yield %: 0.00
GF Value™: 円530.33 vs. price of 円586.00 (10.5% above fair value)
No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Human Metabolome Technologies Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6090 has been successfully added to your 
